SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equivalent in lie ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Susan Pietropaolo - MD, Corporate Communications and IR William Rice - Chairman, President and CEO Rafael Bejar - SVP and CMO Fletcher Payne - SVP, CFO, and CBO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon. My name is Josh and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences' Conference Call for the Fir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

[Corporate and Clinical Update](index=1&type=section&id=Corporate%20and%20Clinical%20Update) Aptose is advancing its lead drug, Tuspetinib, into a frontline triplet therapy for newly diagnosed AML, with key milestones planned through 2025, while also addressing Nasdaq listing compliance [Key Corporate Highlights](index=1&type=section&id=Key%20Corporate%20Highlights) Aptose has advanced its lead drug, Tuspetinib, into a frontline triplet therapy (TUS+VEN+HMA) for newly diagnosed Acute Myeloid Leukemia (AML), with the protocol submitted to the FDA and clinical sites being activated, supported by extensive data showing a favorable safety profile and broad activity, while also addressing Nasdaq listing compliance issues - The TUS+VEN+HMA triplet therapy protocol for newly diagnosed (ND) AML was submitted to the FDA in Q1 2024 and is now being activated at clinical sites[1](index=1&type=chunk)[4](index=4&type=chunk) - The triplet therapy aims to improve upon the current VEN+HMA standard of care by increasing response rates and prolonging survival, particularly for patients who respond poorly to VEN-containing regimens[2](index=2&type=chunk) - Tuspetinib has demonstrated a favorable safety profile with no treatment-related QTc prolongation, differentiation syndrome, or drug-related deaths in prior trials[3](index=3&type=chunk) - Aptose regained compliance with a Nasdaq listing rule concerning a private placement after amending warrant terms with Hanmi Pharmaceutical[7](index=7&type=chunk) - The company received a second Nasdaq non-compliance notice for its stockholders' equity falling below the **$2.5 million** minimum as of December 31, 2023, but equity has since turned positive to **$137,000** as of March 31, 2024[8](index=8&type=chunk) [Upcoming Milestones](index=2&type=section&id=Multiple%20Planned%20Value-creating%20Milestones%20Ahead) Aptose has outlined a series of key milestones for its Tuspetinib triplet therapy program, starting with data presentation at EHA 2024, followed by the initiation and dose escalation of the pilot study in 2024, and culminating in the planned initiation of a pivotal Phase 2/3 program in the second half of 2025 Planned Milestones for Tuspetinib Triplet Program | Milestone | Expected Timing | | :--- | :--- | | TUS+VEN data presentation in R/R AML | EHA 2024 | | Triplet pilot dose initiation in ND AML | Summer 2024 | | Triplet pilot early data (CR/MRD/safety) | ASH 2024 | | Triplet pilot completion and dose selection | EHA 2025 | | Triplet Ph2/Ph3 pivotal program initiation | 2H 2025 | [Financial Results for Q1 2024](index=2&type=section&id=FINANCIAL%20RESULTS%20OF%20OPERATIONS) Aptose reported a reduced net loss in Q1 2024 due to decreased operating expenses, with its financial position showing positive stockholders' equity and sufficient cash to fund operations through August 2024 [Summary of Operations](index=2&type=section&id=Summary%20of%20Operations) For the first quarter of 2024, Aptose reported a net loss of $9.6 million, or $0.73 per share, representing a significant reduction from the $13.7 million net loss, or $2.22 per share, in the same period of 2023, driven by decreased operating expenses Q1 2024 Statement of Operations Highlights (in thousands, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Research and development | $6,445 | $8,811 | | General and administrative | $3,315 | $5,285 | | **Operating expenses** | **$9,760** | **$14,096** | | **Net loss** | **$(9,640)** | **$(13,676)** | | Net Loss per share | $(0.73) | $(2.22) | - The decrease in net loss was primarily due to a **$2.4 million** reduction in R&D costs and a **$2.0 million** reduction in general and administrative costs compared to Q1 2023[13](index=13&type=chunk) [Financial Position](index=3&type=section&id=Financial%20Position) As of March 31, 2024, Aptose had $9.3 million in cash, cash equivalents, and short-term investments, with stockholders' equity turning positive to $0.14 million from a deficit of $2.9 million at the end of 2023, and management expects the current cash position to fund operations through August 2024 Balance Sheet Data (in thousands) | Metric | March 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents and short-term investments | $9,328 | $9,252 | | Working capital | $(318) | $(3,375) | | Total assets | $12,796 | $12,989 | | Stockholders' equity | $137 | $(2,901) | - The company projects its current cash and available capital are sufficient to fund planned operations through August 2024[14](index=14&type=chunk) [Research and Development (R&D) Expenses Analysis](index=3&type=section&id=RESEARCH%20AND%20DEVELOPMENT%20EXPENSES) R&D expenses for Q1 2024 decreased by $2.4 million to $6.4 million compared to the same period in 2023, primarily driven by lower program costs for Tuspetinib due to the near completion of APTIVATE trials and a significant decrease in costs for the Luxeptinib program as certain clinical activities concluded R&D Expenses Breakdown (in thousands) | Program | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Tuspetinib | $3,923 | $4,774 | | Luxeptinib | $208 | $1,289 | | Personnel related expenses | $1,954 | $2,078 | | Stock-based compensation | $328 | $652 | | **Total R&D Expenses** | **$6,445** | **$8,811** | - Tuspetinib program costs decreased due to the near completion of APTIVATE clinical trials and reduced manufacturing costs[17](index=17&type=chunk) - Luxeptinib program costs fell by approximately **$1.1 million** due to the conclusion of certain clinical trial and manufacturing activities[18](index=18&type=chunk) [Corporate Information](index=4&type=section&id=Corporate%20Information) Aptose Biosciences is a clinical-stage biotechnology company focused on precision oncology, with its report containing forward-looking statements subject to inherent risks and uncertainties [About Aptose](index=4&type=section&id=About%20Aptose) Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision oncology medicines, particularly for hematologic malignancies, with a pipeline featuring two oral kinase inhibitors: tuspetinib for AML and luxeptinib for other relapsed or refractory hematologic malignancies - Aptose is a clinical-stage biotech company developing precision medicines for unmet needs in oncology, with an initial focus on hematology[21](index=21&type=chunk) - The company's pipeline includes two oral kinase inhibitors: tuspetinib for AML and luxeptinib for relapsed or refractory hematologic malignancies[21](index=21&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward%20Looking%20Statements) This press release includes forward-looking statements concerning the company's clinical development plans, the potential of its drug candidates, trial timelines, and its financial runway, which are subject to significant risks and uncertainties, and actual results may differ materially from expectations - The report contains forward-looking statements regarding clinical development plans, the potential of tuspetinib, clinical trial timelines, and the company's capital resources[22](index=22&type=chunk) - These statements are subject to risks and uncertainties, and the company does not assume any obligation to update them[23](index=23&type=chunk)

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company de ...

Core Viewpoint - Aptose Biosciences (APTO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is expected to lead to increased buying pressure and a rise in stock price [1][2]. Earnings Estimates and Stock Price Impact - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying and selling decisions, which in turn affects stock prices [3]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [4]. - The system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are considered for strong ratings, indicating superior earnings estimate revisions [6]. Earnings Estimate Revisions for Aptose Biosciences - For the fiscal year ending December 2024, Aptose Biosciences is expected to report earnings of -$3.31 per share, reflecting a 56.3% change from the previous year [5]. - Over the past three months, the Zacks Consensus Estimate for Aptose has increased by 41.6%, indicating a positive trend in earnings estimates [5]. Positioning in Zacks Coverage - The upgrade to Zacks Rank 2 places Aptose Biosciences in the top 20% of Zacks-covered stocks, suggesting potential for upward movement in stock price in the near term [7].

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants Soumit Roy - Jones Research Operator Good afternoon. My name is Jonathan and I will be your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Biosciences Inc. (Exact name of Registrant as specified in its Charter) Canada 98-1136802 (State or other jurisdiction o ...

Financial Performance - Aptose reported a net loss of $51.2 million for the year ended December 31, 2023, an increase of $9.4 million compared to a net loss of $41.8 million in 2022[12]. - Cash and cash equivalents decreased to $9.3 million as of December 31, 2023, down from $47.0 million at the end of 2022[10]. - Total shareholders' equity decreased to $(2.9) million as of December 31, 2023, compared to $37.7 million in 2022[10]. Research and Development - Research and development expenses rose to $36.8 million in 2023, up $8.7 million from $28.1 million in 2022, primarily due to increased costs associated with the tuspetinib program[14]. - Tuspetinib achieved a complete response/complete response with partial hematologic recovery (CR/CRh) rate of 36% among patients naive to venetoclax at the recommended Phase 2 dose of 80 mg[5]. - The G3 formulation of luxeptinib demonstrated approximately 10-fold better absorption compared to the original G1 formulation, achieving desired plasma exposure levels[7]. - The company plans to initiate a pilot triplet study of tuspetinib, venetoclax, and a hypomethylating agent in frontline therapy for newly diagnosed AML patients in Summer 2024[8]. Capital and Funding - The company completed a public offering on January 30, 2024, raising approximately $9.7 million from the sale of 5,649,122 common shares at $1.71 per share[3]. - A private placement with Hanmi Pharmaceutical on January 31, 2024, generated $4 million, with shares sold at $1.90 each, an 11% premium over the public offering price[4]. Risks and Uncertainties - The company acknowledges significant risks and uncertainties that could impact future results, including capital acquisition for research and operations[23]. - Early-stage drug development risks include demonstrating efficacy, development time/cost, and regulatory approval processes[23]. - There is a potential risk of new manufacturers failing to produce acceptable GMP batches in sufficient quantities[23]. - Unexpected manufacturing defects are highlighted as a significant risk factor[23]. - The company does not intend to update forward-looking statements unless required by law, indicating a cautious approach to investor communications[24]. - Investors are advised not to overly rely on forward-looking statements due to inherent uncertainties[24]. Administrative Expenses - General and administrative expenses increased to $15.6 million in 2023, up from $14.5 million in 2022, driven by higher salaries and professional fees[17].

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:li ...